Related Experiment Video
Updated: Dec 8, 2025
09:44
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
10.8K
; PARAMETERS OF FIBRINOLYTIC AND ANTIFIBRINOLYTIC ACTIVITY IN PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS ASSOCIATED WITH
1Ivano-Frankivsk National Medical University, Ukraine.
Georgian Medical News
|September 23, 2020
Summary
Patients with alcoholic liver cirrhosis (ALC) show altered fibrinolysis, especially with adiposity. Increased tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) indicate a higher thrombotic risk.
Area of Science:
- Hepatology
- Hematology
- Biochemistry
Background:
- Alcoholic liver cirrhosis (ALC) is a significant health issue.
- Fibrinolytic and antifibrinolytic systems play crucial roles in hemostasis.
- Adiposity and disease decompensation can influence coagulation in ALC patients.
Purpose of the Study:
- To investigate changes in fibrinolytic and antifibrinolytic parameters in ALC patients.
- To assess the impact of adiposity and disease severity on these changes.
- To determine the potential thrombotic risk associated with these alterations.
Main Methods:
- Study included 104 ALC patients (66 with adiposity) and 20 healthy controls.
- Circulating biomarkers of fibrinolysis and antifibrinolysis were measured using immunoassay.
- Disease severity was assessed using the Child-Pugh score.
Main Results:
- ALC patients exhibited elevated levels of tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), and plasma-α2-antiplasmin (PAP) complexes.
- These increases were more pronounced in patients with concomitant adiposity and correlated with worsening Child-Pugh scores.
- A decreased tPA/PAI-1 index and elevated D-dimers were observed, indicating a prothrombotic state.
Conclusions:
- Increased t-PA, PAI-1, and PAP, along with a reduced tPA/PAI-1 index, suggest a prothrombotic state in ALC.
- Concomitant adiposity exacerbates these fibrinolytic and antifibrinolytic alterations.
- These findings highlight the risk of thrombosis in ALC patients, particularly those with obesity.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
101
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
101
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
125
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
125
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
368
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
368
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
96
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
96
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
119
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
119
01:26Atherosclerosis III: Management
223
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
223